Bristol Myers Squibb to Acquire Orbital Therapeutics to Advance Next-Gen RNA Medicines
Bristol Myers Squibb and Orbital Therapeutics announced a definitive agreement under which BMS will acquire Orbital, a privately held biotechnology company pioneering a new generation of RNA medicines that reprogram the immune system in vivo, enabling treatments that provide the precision, control, and flexibility nee…
